Drug adherence in hypertension

Pathophysiology and Pharmacotherapy of Cardiovascular Disease

Volumn , Issue , 2015, Pages 919-933

  Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Drug measurements; Electronic monitoring; Healthcare system; Multidiscipline; Persistence; Resistant hypertension

Indexed keywords

EID: 84944104718     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-15961-4_43     Document Type: Chapter

References (67)

1. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2013;31(10): 1925-38.
2. James PA, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.
3. National Clinical Guideline Centre. National Institute for Health and Clinical Excellence: Guidance. In: Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34. London: Royal College of Physicians (UK) National Clinical Guideline Centre; 2011.
4. Kearney PM, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22(1):11-9.
5. Benetos A, et al. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens. 2003;21(9):1635-40.
6. Mancia G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril study. Hypertension. 2007;50(2):299-305.
7. Burnier M. Blood pressure control and the implementation of guidelines in clinical practice: can we fill the gap? J Hypertens. 2002;20(7):1251-3.
8. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882-7.e1.
9. Vrijens B, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705.
10. Blaschke TF, et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275-301.
11. Vrijens B, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114-7.
12. Morisky DE, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-54.
13. Halpern MT, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039-48.
14. Hasselstrom J, et al. The Swedish Primary Care Cardiovascular Database (SPCCD): 74 751 hypertensive primary care patients. Blood Press. 2014;23(2):116-25.
15. Qvarnstrom M, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69(11):1955-64.
16. Jung O, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766-74.
17. Tomaszewski M, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855-61.
18. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150(7):1509-10.
19. Strauch B, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455-61.
20. Burnier M, et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218-25.
21. Simpson SH, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.
22. Granger BB, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366(9502):2005-11.
23. Krousel-Wood MA, et al. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93(3):753-69.
24. Maimaris W, et al. The influence ofhealth systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med. 2013;10(7):e1001490.
25. Christensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens. 2009;27(8):1540-51.
26. Wetzels GE, et al. Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens. 2007;20(2):119-25.
27. Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesar- tan and ramipril. Int J Clin Pract. 2011;65(2):127-33.
28. Mallion JM, et al. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens Suppl. 1998;16(1):S75-9.
29. Bramley TJ, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239-45.
30. Corrao G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610-8.
31. Perreault S, et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol. 2010;69(1):74-84.
32. Perreault S, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266(2):207-18.
33. Kettani FZ, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213-20.
34. Kumar N, Calhoun DA, Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control. 2013;6:139-51.
35. Burnier M. Managing ‘resistance’: is adherence a target for treatment? Curr Opin Nephrol Hypertens. 2014;23(5):439-43.
36. de la Sierra A, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898-902.
37. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-80.
38. Persu A, et al. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension. 2014;63(6):1319-25.
39. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28(8):463-8.
40. Burnier M, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens. 2001;19(2):335-41.
41. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990;150(7):1377-8.
42. Smith SM, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635-43.
43. Fadl Elmula FE, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63(5):991-9.
44. Bunker J, et al. How common is true resistant hypertension? J Hum Hypertens. 2011;25(2):137-40.
45. Gwadry-Sridhar FH, et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health. 2013;16(5):863-71.
46. McManus RJ, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312(8):799-808.
47. Parati G, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24(12):779-85.
48. Marquez-Contreras E, et al. Non-compliance and inertia in hypertensive Spaniards at high cardiovascular risk: CUMPLE study. Curr Med Res Opin. 2014;30(1):11-7.
49. Coleman CI, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527-39.
50. Iskedjian M, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24(2):302-16.
51. Burnier M, et al. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract. 2009;63(5):790-8.
52. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-6.
53. Castellano JM, et al. A polypill strategy to improve adherence: results from FOCUS (fixed- dose combination drug for secondary cardiovascular prevention) project. J Am Coll Cardiol. 2014;64:2071.
54. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
55. Selak V, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318.
56. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;(2):CD004804.
57. Neri L, et al. Regimen complexity and prescription adherence in dialysis patients. Am J Nephrol. 2011;34(1):71-6.
58. Lowy A, et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. Int J Clin Pract. 2011;65(1):41-53.
59. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003;60(7):657-65.
60. Brunenberg DE, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics. 2007;25(3):239-51.
61. Omboni S, et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31(3):455-67; discussion 467-8.
62. Schneider MP, Burnier M. On-line home monitoring of drug compliance: is it feasible? Eur J Clin Pharmacol. 1998;54(6):489-90.
63. Santschi V, et al. Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. Eur J Intern Med. 2008;19(6):427-34.
64. Santschi V, et al. Improving blood pressure control through pharmacist interventions: a metaanalysis of randomized controlled trials. J Am Heart Assoc. 2014;3(2):e000718.
65. Van Zuilen AD, et al. MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol. 2008;21(3):261-7.
66. Chapman RH, et al. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract. 2010;64(2):169-81.
67. Levi F, et al. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002;88(2):119-24.